{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 52,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide presents two patient case studies with MRI scans showing tumor reduction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/43",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.18,
        "x": 0.29,
        "y": 0.34
      },
      "kind": "image",
      "text": "MRI scans showing baseline and 12 weeks",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d889d57-d55d-4b7c-8808-95988cc772b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.18,
        "x": 0.73,
        "y": 0.34
      },
      "kind": "image",
      "text": "MRI scans showing baseline and 6 weeks",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6ade690-c906-4df8-8594-1541eb92657c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.27,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "EML4-ALK fusion NSCLC with ALK L1196Q resistance mutation; 3 lines of therapy; NVL-655 (150 mg QD); CNS PR after ~6 weeks; Treatment continues at 3.7 months with ongoing confirmed CNS PR (-59%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ca17644-a77b-4fe3-93b9-ba3cfaaa96b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.27,
        "x": 0.09,
        "y": 0.32
      },
      "kind": "list",
      "text": "EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases after ~5 weeks; Treatment continues at 4.2 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2874121-db60-494b-9427-a6fc9bbc9d9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.38,
        "x": 0.09,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Intracranial Complete Response in EML4-ALK fusion NSCLC:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cd4f212-d1cd-4a7e-9120-1e6a575df42b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.38,
        "x": 0.53,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Intracranial Partial Response in ALK L1196Q NSCLC:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1a775f6-1c0e-442a-86cb-9e1a9256f2ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Data as of 8 August 2023. CNS, central nervous system; CR, complete response; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1cebae0-7045-4d36-bdc7-7ad2625540c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "CNS Activity | NVL-655 Induced Intracranial Responses in Patients with TKI-Refractory ALK+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "868e37f4-f9b8-42dc-9fea-8100ef0e6fe9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}